Search research articles
Contact Us
Filters
Showing results (41-50 of 75) with videos related to
Page
of 8
Sort By:
Leukemia Research
|
August 22, 2016
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)
Farhad Ravandi, Ivana Gojo, Mrinal M Patnaik, et al.
Journal of the National Cancer Institute
|
February 15, 2014
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents
Bing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Blood
|
January 24, 2012
RNAi screening of the kinome with cytarabine in leukemias
Raoul Tibes, James M Bogenberger, Leena Chaudhuri, et al.
JAMA Oncology
|
February 3, 2017
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia
Natalie Ertz-Archambault, Heidi Kosiorek, Gretchen E Taylor, et al.
Investigational New Drugs
|
December 14, 2011
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
Glen J Weiss, Manuel Hidalgo, Mitesh J Borad, et al.
Oncotarget
|
January 2, 2018
Combined venetoclax and alvocidib in acute myeloid leukemia
James Bogenberger, Clifford Whatcott, Nanna Hansen, et al.
Investigational New Drugs
|
May 3, 2015
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies
Guillermo Garcia-Manero, Raoul Tibes, Tapan Kadia, et al.
Haematologica
|
November 2, 2013
CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo
Leena Chaudhuri, Nicole D Vincelette, Brian D Koh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2011
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors
Patricia M LoRusso, Charles M Rudin, Josina C Reddy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies
Glen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 75) with videos related to
Sort By:
Page
of 8
Leukemia Research
|
August 22, 2016
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)
Farhad Ravandi, Ivana Gojo, Mrinal M Patnaik, et al.
Journal of the National Cancer Institute
|
February 15, 2014
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents
Bing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Blood
|
January 24, 2012
RNAi screening of the kinome with cytarabine in leukemias
Raoul Tibes, James M Bogenberger, Leena Chaudhuri, et al.
JAMA Oncology
|
February 3, 2017
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia
Natalie Ertz-Archambault, Heidi Kosiorek, Gretchen E Taylor, et al.
Investigational New Drugs
|
December 14, 2011
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
Glen J Weiss, Manuel Hidalgo, Mitesh J Borad, et al.
Oncotarget
|
January 2, 2018
Combined venetoclax and alvocidib in acute myeloid leukemia
James Bogenberger, Clifford Whatcott, Nanna Hansen, et al.
Investigational New Drugs
|
May 3, 2015
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies
Guillermo Garcia-Manero, Raoul Tibes, Tapan Kadia, et al.
Haematologica
|
November 2, 2013
CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo
Leena Chaudhuri, Nicole D Vincelette, Brian D Koh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2011
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors
Patricia M LoRusso, Charles M Rudin, Josina C Reddy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies
Glen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.
Page
of 8